{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:56:40Z","timestamp":1793048200732,"version":"4.5.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304104"],"award-info":[{"award-number":["2022YFC2304104"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222066"],"award-info":[{"award-number":["82222066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104081"],"award-info":[{"award-number":["82104081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20783"],"award-info":[{"award-number":["U24A20783"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.apsb.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:40:36Z","timestamp":1762360836000},"page":"2153-2173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid-based nanosystems for atherosclerosis treatment: Evolving approaches and novel therapeutic strategies"],"prefix":"10.1016","volume":"16","author":[{"given":"Lijun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0278-3712","authenticated-orcid":false,"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-1046","authenticated-orcid":false,"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.11.001_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114709","article-title":"Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment","volume":"194","author":"Zhang","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","volume":"19","author":"Chen","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: roles of innate and adap tive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.11.001_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.11.001_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jconrel.2021.03.034","article-title":"Atherosclerosis: conventional intake of cardiovascular drugs versus delivery using nanotechnology\u2014a new chance for causative therapy?","volume":"333","author":"Groner","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biomaterials.2017.07.035","article-title":"Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis","volume":"143","author":"Dou","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.11.001_bib8","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1073\/pnas.1303377110","article-title":"Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles","volume":"110","author":"Kamaly","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.11.001_bib9","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1021\/acsnano.6b01114","article-title":"Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis","volume":"10","author":"Kamaly","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.addr.2008.03.014","article-title":"Multifunctional magnetic nanoparticles for targeted imaging and therapy","volume":"60","author":"McCarthy","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-024-01574-1","article-title":"Lipid-based nanosystems: the next generation of cancer immune therapy","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.11.001_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1208\/s12249-011-9668-0","article-title":"Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells","volume":"12","author":"Gu","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2025.11.001_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2022.102757","article-title":"Liposomes as biocompatible and smart delivery systems\u2014the current state","volume":"309","author":"Dymek","year":"2022","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib15","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2014from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib16","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","article-title":"New developments in liposomal drug delivery","volume":"115","author":"Pattni","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903156","article-title":"On the structure of solid lipid nanoparticles","volume":"15","author":"Pink","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.11.001_bib19","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.2147\/IJN.S478964","article-title":"Advancements and challenges of nanostructured lipid carriers for wound healing applications","volume":"19","author":"Wathoni","year":"2022","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.11.001_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425247.2020.1727883","article-title":"SLN and NLC for topical, dermal, and transdermal drug delivery","volume":"17","author":"Souto","year":"2020","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2025.11.001_bib21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s13346-021-01071-9","article-title":"Lipid-based emulsion drug delivery systems\u2014a comprehensive review","volume":"12","author":"Dhaval","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2025.11.001_bib22","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","article-title":"Lipid carriers for mRNA delivery","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nano.2017.12.021","article-title":"Protein corona and phospholipase activity drive selective accumulation of nanomicelles in atherosclerotic plaques","volume":"14","author":"Lechuga-Vieco","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2025.11.001_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1049\/nbt2.12018","article-title":"Nanomicelles: types, properties and applications in drug delivery","volume":"15","author":"Bose","year":"2021","journal-title":"IET Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","article-title":"Recent advancements in liposome technology","volume":"156","author":"Filipczak","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2010.02.029","article-title":"Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles","volume":"144","author":"Zhigaltsev","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108755","article-title":"PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines","volume":"35","author":"Xiao","year":"2024","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.001_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd3578","article-title":"Perspectives and opportunities for nanomedicine in the management of atherosclerosis","volume":"10","author":"Lobatto","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.11.001_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2023.06.035","article-title":"Injectable liposomal docosahexaenoic acid alleviates atherosclerosis progression and enhances plaque stability","volume":"360","author":"Chong","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib30","doi-asserted-by":"crossref","first-page":"16211","DOI":"10.1039\/D3RA01822A","article-title":"Synthetic ditempolphosphatidylcholine liposome-like nanoparticles for anti-oxidative therapy of atherosclerosis","volume":"13","author":"Wang","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2025.11.001_bib31","doi-asserted-by":"crossref","first-page":"13759","DOI":"10.1021\/acsnano.8b08875","article-title":"Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy","volume":"13","author":"Beldman","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.biomaterials.2015.02.089","article-title":"Hyaluronic acid nanoparticles for active targeting atherosclerosis","volume":"53","author":"Lee","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.11.001_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.1306","article-title":"Non-clinical evaluation of YN001\u2014a promising drug for atherosclerotic therapy by targeted delivery system","volume":"44","author":"Ma","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2025.11.001_bib34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.actbio.2023.11.020","article-title":"An elastase-inhibiting, plaque-targeting and neutrophil-hitchhiking liposome against atherosclerosis","volume":"173","author":"Shi","year":"2024","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2025.11.001_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/pharmaceutics14051083","article-title":"Targeting peptide, fluorescent reagent modified magnetic liposomes coated with rapamycin target early atherosclerotic plaque and therapy","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.11.001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155274","article-title":"VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis","volume":"135","author":"Jia","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.apsb.2025.11.001_bib37","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3390\/molecules29122873","article-title":"Nanoparticles as drug delivery systems for the targeted treatment of atherosclerosis","volume":"29","author":"Pang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.11.001_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123102","article-title":"Low molecular weight fucoidan modified nanoliposomes for the targeted delivery of the anti-inflammation natural product berberine","volume":"642","author":"Liu","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib39","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1055\/s-0042-1751036","article-title":"Lipid-based nanocarrier systems for drug delivery: advances and applications","volume":"4","author":"Zhao","year":"2022","journal-title":"Pharmaceutical Fronts"},{"key":"10.1016\/j.apsb.2025.11.001_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications","volume":"8","author":"M\u00fcller","year":"2011","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.apsb.2025.11.001_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib42","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.3390\/molecules24193499","article-title":"Biodistribution of nanostructured lipid carriers in mice atherosclerotic model","volume":"24","author":"Devel","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.11.001_bib43","article-title":"Nanostructured lipid carriers accumulate in atherosclerotic plaques of Apoe\u2212\/\u2212 mice","volume":"25","author":"Vigne","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2025.11.001_bib44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/acs.bioconjchem.5b00590","article-title":"Solid lipid nanoparticles for image\u2014guided therapy of atherosclerosis","volume":"27","author":"Oumzil","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.11.001_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122258","article-title":"A nano-enabled biotinylated anti-LDL theranostic system to modulate systemic LDL cholesterol","volume":"628","author":"du Toit","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijpharm.2010.03.011","article-title":"Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug","volume":"391","author":"Zhang","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10557-014-6566-1","article-title":"Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits","volume":"29","author":"Leite","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.apsb.2025.11.001_bib48","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.atherosclerosis.2007.12.051","article-title":"Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit","volume":"197","author":"Maranhao","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2025.11.001_bib49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/1061186X.2020.1859514","article-title":"Improving protection effects of eucalyptol via carboxymethyl chitosan-coated lipid nanoparticles on hyperglycaemia-induced vascular endothelial injury in rats","volume":"29","author":"Peng","year":"2021","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2025.11.001_bib50","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1021\/acsnano.2c12230","article-title":"Fabrication of a polysaccharide-protein\/protein complex stabilized oral nanoemulsion to facilitate the therapeutic effects of 1,8-cineole on atherosclerosis","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib51","article-title":"Targeting the microenvironment of vulnerable atherosclerotic plaques: an emerging diagnosis and therapy strategy for atherosclerosis","volume":"34","author":"Zhang","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib52","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.3390\/ijms22105188","article-title":"A nano-emulsion platform functionalized with a fully human scFv-Fc antibody for atheroma targeting: towards a theranostic approach to atherosclerosis","volume":"22","author":"Bonnet","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijpharm.2017.09.010","article-title":"Iron oxide core oil-in-water nanoemulsion as tracer for atherosclerosis MPI and MRI imaging","volume":"532","author":"Prevot","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib54","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1039\/D3NR06507C","article-title":"Sphingomyelinase-responsive nanomicelles for targeting atherosclerosis","volume":"16","author":"Mu\u00f1oz-Hernando","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2025.11.001_bib55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2217\/nnm-2017-0099","article-title":"Polymeric nanomicelles: a potential hazard for the cardiovascular system?","volume":"12","author":"Wang","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2025.11.001_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102304","article-title":"Circulating monocyte differentiation-activated nanoprodrugs for reprogramming macrophage immunity in atherosclerotic plaques","volume":"56","author":"Fu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2025.11.001_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for o ligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.11.001_bib59","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2025.11.001_bib61","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1161\/ATVBAHA.119.313253","article-title":"Anti-inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques","volume":"39","author":"Fotakis","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2025.11.001_bib62","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41556-022-01030-7","article-title":"LDL delivery of microbial small RNAs drives atherosclerosis through macrophage TLR8","volume":"24","author":"Allen","year":"2022","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2025.11.001_bib63","doi-asserted-by":"crossref","first-page":"24206","DOI":"10.1021\/acsami.4c00999","article-title":"Acoustic delivery of plasma low-density lipoprotein into liver via ApoB100-targeted microbubbles inhibits atherosclerotic plaque growth","volume":"16","author":"Li","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.11.001_bib64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.addr.2020.08.003","article-title":"Lipoprotein-based drug delivery","volume":"159","author":"Busatto","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.11.001_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib67","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jconrel.2023.11.057","article-title":"Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications","volume":"365","author":"Yang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib68","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.apsb.2021.01.020","article-title":"Cell membrane-derived vesicles for delivery of therapeutic agents","volume":"11","author":"Le","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib69","doi-asserted-by":"crossref","first-page":"17080","DOI":"10.1021\/acsnano.1c03800","article-title":"Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation","volume":"15","author":"Chugh","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib70","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/jacs.0c09029","article-title":"Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation","volume":"143","author":"Li","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.11.001_bib71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","article-title":"Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery","volume":"344","author":"Maeki","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanop articles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib73","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt0918-777","article-title":"Alnylam launches era of RNAi drugs","volume":"36","author":"Garber","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.11.001_bib75","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.11.001_bib76","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nbt.1989","article-title":"Therapeutic siRNA silencing in inflammatory monocytes in mice","volume":"29","author":"Leuschner","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib77","doi-asserted-by":"crossref","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1063","article-title":"siRNA nanoparticles targeting CaMKII\u03b3 in lesional macrophages improve atherosclerotic plaque stability in mice","volume":"12","author":"Tao","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2014.84","article-title":"In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight","volume":"9","author":"Dahlman","year":"2014","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib80","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s42255-019-0102-3","article-title":"Endothelial TGF-\u03b2 signalling drives vascular inflammation and atherosclerosis","volume":"1","author":"Chen","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.apsb.2025.11.001_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/10717544.2017.1384518","article-title":"Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.11.001_bib82","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncpcardio0661","article-title":"Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention","volume":"3","author":"Navab","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib83","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1021\/nn4039063","article-title":"Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics","volume":"7","author":"Kim","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109584","article-title":"A natural nano-platform: advances in drug delivery system with recombinant high-density lipoprotein","volume":"35","author":"Xie","year":"2024","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.001_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.apsb.2017.11.006","article-title":"Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery","volume":"8","author":"Ma","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib86","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1038\/ncomms4065","article-title":"A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation","volume":"5","author":"Duivenvoorden","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.11.001_bib87","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1172\/JCI119223","article-title":"Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells","volume":"99","author":"Atger","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.11.001_bib88","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1039\/C9TB02101A","article-title":"Shuttle\/sink model composed of \u03b2-cyclodextrin and simvastatin-loaded discoidal reconstituted high-density lipoprotein for enhanced cholesterol efflux and drug uptake in macrophage\/foam cells","volume":"8","author":"He","year":"2020","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2025.11.001_bib89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.chemphyslip.2019.01.009","article-title":"The ApoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage","volume":"219","author":"White","year":"2019","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.apsb.2025.11.001_bib90","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2011.05.029","article-title":"Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide\/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits","volume":"218","author":"Iwata","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2025.11.001_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202105915","article-title":"Boosting cholesterol efflux from foam cells by sequential administrati on of rHDL to deliver microRNA and to remove cholesterol in a triple-cell 2D atherosclerosis model","volume":"18","author":"Jebari-Benslaiman","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.11.001_bib92","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","article-title":"High-density lipoproteins: nature's multifunctional nanoparticles","volume":"10","author":"Kuai","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib93","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2016.04.020","article-title":"Lipoproteins and lipoprotein mimetics for imaging and drug delivery","volume":"106","author":"Thaxton","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib94","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/10717544.2021.1886199","article-title":"Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential","volume":"28","author":"Di","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.11.001_bib95","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10557-016-6675-0","article-title":"Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles","volume":"30","author":"Daminelli","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.apsb.2025.11.001_bib96","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7555\/JBR.31.20160123","article-title":"Evaluation of atherosclerotic lesions in cholesterol-fed mice during t reatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study","volume":"31","author":"D Lima","year":"2017","journal-title":"J Biomed Res"},{"key":"10.1016\/j.apsb.2025.11.001_bib97","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1248\/bpb.24.925","article-title":"Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice","volume":"24","author":"Tauchi","year":"2001","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2025.11.001_bib98","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41569-020-0407-7","article-title":"Developing a vaccine against atherosclerosis","volume":"17","author":"Hansson","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib99","article-title":"Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases","volume":"18","author":"Wang","year":"2023","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib101","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.3390\/ijms22115487","article-title":"Extracellular vesicles as potential therapeutics for inflammatory diseases","volume":"22","author":"Hwang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav8521","article-title":"Advances in therapeutic applications of extracellular vesicles","volume":"11","author":"Wiklander","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105692","article-title":"The role of extracellular vesicles in regulating local and systemic inflammation in cardiovascular disease","volume":"170","author":"Ohayon","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2025.11.001_bib104","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41569-023-00883-1","article-title":"Flow-induced reprogramming of endothelial cells in atherosclerosis","volume":"20","author":"Tamargo","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110756","article-title":"Endothelial progenitor cell-derived exosomes ameliorate endothelial dysfunction in a mouse model of diabetes","volume":"131","author":"Bai","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.11.001_bib106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/ncb2441","article-title":"Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs","volume":"14","author":"Hergenreider","year":"2012","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2025.11.001_bib107","first-page":"447","article-title":"Engineered M2 macrophage-derived extracellular vesicles with platelet membrane fusion for targeted therapy of atherosclerosis","volume":"35","author":"Xie","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib108","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1002\/anie.201913700","article-title":"Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment","volume":"59","author":"Wu","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.11.001_bib109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2017.04.016","article-title":"Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response","volume":"154","author":"Li","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.apsb.2025.11.001_bib110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature15373","article-title":"Nanoparticle biointerfacing by platelet membrane cloaking","volume":"526","author":"Hu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.11.001_bib111","article-title":"Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management","volume":"6","author":"Wang","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib112","doi-asserted-by":"crossref","first-page":"33862","DOI":"10.1021\/acsami.1c07821","article-title":"\u201cPlug and play\u201d functionalized erythrocyte nanoplatform for target atherosclerosis management","volume":"13","author":"Zhong","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.11.001_bib113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2024.07.013","article-title":"From bench to bedside: platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery","volume":"373","author":"Safdar","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.127296","article-title":"Biomimetic liposomes hybrid with platelet membranes for targeted therapy of atherosclerosis","volume":"408","author":"Song","year":"2021","journal-title":"Chem Eng J"},{"key":"10.1016\/j.apsb.2025.11.001_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401113","article-title":"A macrophage membrane-functionalized, reactive oxygen species-activatable nanoprodrug to alleviate inflammation and improve the lipid metabolism for atherosclerosis management","volume":"13","author":"Qu","year":"2024","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib116","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1038\/s41467-020-16439-7","article-title":"Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines","volume":"11","author":"Gao","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.11.001_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202204822","article-title":"Biomimetic macrophage membrane and lipidated peptide hybrid nanovesicles for atherosclerosis therapy","volume":"32","author":"Guo","year":"2022","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib118","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1021\/acsnano.3c00288","article-title":"Neutrophil-membrane-coated biomineralized metal\u2014organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122505","article-title":"Biomimetic nanodrug targets inflammation and suppresses YAP\/TAZ to ameliorate atherosclerosis","volume":"306","author":"Huang","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.11.001_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2025.111093","article-title":"Engineered bacteria potentiate cancer immunotherapy","volume":"36","author":"Sun","year":"2025","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.001_bib121","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.apsb.2022.10.022","article-title":"Cell-derived nanovesicles from mesenchymal stem cells as extracellular vesicle-mimetics in wound healing","volume":"13","author":"Neupane","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib122","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1021\/acsnano.8b04066","article-title":"Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics","volume":"12","author":"Li","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.11.001_bib123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.apsb.2017.11.009","article-title":"Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment","volume":"8","author":"Li","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.001_bib124","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.3390\/foods13182886","article-title":"Targeting gut microbiota with probiotics and phenolic compounds in the treatment of atherosclerosis: a comprehensive review","volume":"13","author":"Cruz Neto","year":"2024","journal-title":"Foods"},{"key":"10.1016\/j.apsb.2025.11.001_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.136198","article-title":"Overexpressed VLA-4 on endothelial cell membrane camouflaging the pathological reactive oxygen species responsive prodrug to enhance target therapy for atherosclerosis","volume":"442","author":"Zhong","year":"2022","journal-title":"Chem Eng J"},{"key":"10.1016\/j.apsb.2025.11.001_bib126","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12951-024-02463-y","article-title":"Targeted delivery of MerTK protein via cell membrane engineered nanopa rticle enhances efferocytosis and attenuates atherosclerosis in diabetic Apoe\u2212\/\u2212 mice","volume":"22","author":"Qiu","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib127","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202003253","article-title":"ROS responsive nanoplatform with two-photon AIE imaging for atherosclerosis diagnosis and \u201ctwo-pronged\u201d therapy","volume":"16","author":"Ma","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.11.001_bib128","article-title":"Site-specific microRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity","volume":"30","author":"Li","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib129","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1016\/j.jbiomech.2010.07.011","article-title":"Wall shear over high degree stenoses pertinent to atherothrombosis","volume":"43","author":"Bark","year":"2010","journal-title":"J Biomech"},{"key":"10.1016\/j.apsb.2025.11.001_bib130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nnano.2012.84","article-title":"Shear-stress sensitive lenticular vesicles for targeted drug delivery","volume":"7","author":"Holme","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102530","article-title":"ROS-responsive biomimetic nanovesicles to plaque microenvironment in targeted therapy of atherosclerosis","volume":"59","author":"Zhou","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2025.11.001_bib132","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/IJN.S124252","article-title":"Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy","volume":"12","author":"Zhang","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.11.001_bib133","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jconrel.2025.02.034","article-title":"Macrophage membrane enveloped on double-locked nanoplatform with right-side-out orientation to improving precise theranostic for atherosclerosis","volume":"380","author":"Liu","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202401659","article-title":"Dual-function nanoscale coordination polymer nanoparticles for targete d diagnosis and therapeutic delivery in atherosclerosis","volume":"20","author":"Lin","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.11.001_bib135","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent advances in lipid nanoparticles for delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.11.001_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114197","article-title":"Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids","volume":"184","author":"Prakash","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.11.001_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102871","article-title":"Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment","volume":"314","author":"Grav\u00e1n","year":"2023","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib138","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.11.001_bib139","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2147\/IJN.S29827","article-title":"A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution","volume":"7","author":"Ma","year":"2012","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.11.001_bib140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2022.07.004","article-title":"Statin therapy for the primary prevention of cardiovascular disease: pros","volume":"356","author":"Razavi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2025.11.001_bib141","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5114\/aoms.2015.50972","article-title":"Improvement of hepatic bioavailability as a new step for the future of statin","volume":"11","author":"Petyaev","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib142","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2025.11.001_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221100107","article-title":"A comprehensive review of PCSK9 inhibitors","volume":"27","author":"Coppinger","year":"2022","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.apsb.2025.11.001_bib144","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/ijms26031136","article-title":"Combining colchicine and antiplatelet therapy to tackle atherothrombos is: a paradigm in transition?","volume":"26","author":"Giordano","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.11.001_bib145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/HCO.0000000000001226","article-title":"Hypertension in atherosclerotic cardiovascular disease: insights into epidemiology, management strategies, and outcomes","volume":"40","author":"Gupta","year":"2025","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib146","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1172\/JCI10370","article-title":"Peroxisome proliferator\u2014activated receptor \u03b3 ligands inhibit developme nt of atherosclerosis in LDL receptor\u2013deficient mice","volume":"106","author":"Li","year":"2000","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.11.001_bib147","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2024.05.048","article-title":"ROS-scavenging lipid-based liquid crystalline as a favorable stem cell extracellular vesicles delivery vector to promote wound healing","volume":"371","author":"Li","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.11.001_bib148","article-title":"Deformable hyaluronic acid niosomes overcome multi-barriers for improved ergothioneine transdermal delivery against UV-induced skin damage","author":"Li","year":"2025","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.001_bib149","year":"2019","journal-title":"Alprostadil liposomes for injection for lower extremity arteriosclerosis obliteran of phase II clinical trial"},{"key":"10.1016\/j.apsb.2025.11.001_bib150","year":"2011"},{"key":"10.1016\/j.apsb.2025.11.001_bib151","year":"2012","journal-title":"A proof of concept study to determine the local delivery and efficacy of intravenously injected PEG-liposomal prednisolone sodium phosphate (Nanocort) in atherosclerotic tissue in subjects with peripheral artery disease"},{"key":"10.1016\/j.apsb.2025.11.001_bib152","author":"Phase","year":"2003","journal-title":"single center, non-controlled, open-label study of liposomal prostaglandin E1 (liprostin) as adjunct therapy with lower limb angioplasty in patients with ischemic and non-ischemic peripheral arterial occlusive disease"},{"key":"10.1016\/j.apsb.2025.11.001_bib153","year":"2023","journal-title":"Can loco-regional anesthesia with liposomal bupivacaine reduce intra- and post-operative narcotic use in patients undergoing lower extremity revascularization?. a prospective, triple blinded, randomized trial"},{"key":"10.1016\/j.apsb.2025.11.001_bib154","year":"2019","journal-title":"Treatment of patients with coronary and aortic atherosclerotic disease with paclitaxel-associated to LDL Like nanoparticles. A randomized, double-blind, placebo-control trial"},{"key":"10.1016\/j.apsb.2025.11.001_bib155","year":"2020","journal-title":"Treatment of patients with coronary and aortic atherosclerotic disease with methotrexate-associated to LDL Like nanoparticles. A randomized, double-blind, placebo-control trial"},{"key":"10.1016\/j.apsb.2025.11.001_bib156","article-title":"inventor; Universiteit Utrecht Holding BV; Enceladus Pharmaceuticals BV; Singapore Health Services Pte Ltd., assignees. Liposomal corticosteroids for topical injection in inflamed lesions or areas","author":"Metselaar","year":"2019","journal-title":"Chinese patent CN109906075A"},{"key":"10.1016\/j.apsb.2025.11.001_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1342832","article-title":"Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study","volume":"11","author":"Marinho","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib158","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2025.11.001_bib159","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","article-title":"Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial a randomized clinical trial","volume":"3","author":"Nicholls","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002171","article-title":"Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial","volume":"4","author":"Tricoci","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apsb.2025.11.001_bib161","year":"2023","journal-title":"Deciphering the role of dietary fatty acids on extracellular vesicles-mediated intercellular communication and their implication in atherosclerosis and metabolic syndrome: a multi-omics approach to precision nutrition"},{"key":"10.1016\/j.apsb.2025.11.001_bib162","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12249-019-1293-3","article-title":"Lipid-based nanocarriers for lymphatic transportation","volume":"20","author":"Vishwakarma","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2025.11.001_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2019.104837","article-title":"Lipid nanocarriers for microRNA delivery","volume":"226","author":"Scheideler","year":"2020","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.apsb.2025.11.001_bib164","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.11.001_bib165","article-title":"Non-viral nucleic acid delivery approach: a boon for state-of-the-art gene delivery","volume":"80","author":"Sahu","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2025.11.001_bib166","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.11.001_bib167","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2025.11.001_bib168","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41467-024-45254-7","article-title":"Regulating protein corona on nanovesicles by glycosylated polyhydroxy polymer modification for efficient drug delivery","volume":"15","author":"Miao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.11.001_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.02.002","article-title":"Evolving targets for the treatment of atherosclerosis","volume":"187","author":"Solanki","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.11.001_bib170","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.nano.2015.02.021","article-title":"Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration","volume":"11","author":"van der Valk","year":"2015","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib171","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13238-011-1016-3","article-title":"Animal models for the atherosclerosis research: a review","volume":"2","author":"Li","year":"2011","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2025.11.001_bib172","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOL.0b013e32833ded6a","article-title":"Atherosclerotic lesions in mouse and man: is it the same disease?","volume":"21","author":"Bentzon","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2025.11.001_bib173","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejphar.2017.05.010","article-title":"Animal models of atherosclerosis","volume":"816","author":"Emini","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.11.001_bib174","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41569-024-01023-z","article-title":"Targeting immune cell recruitment in atherosclerosis","volume":"21","author":"D\u00f6ring","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2025.11.001_bib175","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.11.001_bib176","article-title":"Rational design and modular synthesis of biodegradable ionizable lipid s via the Passerini reaction for mRNA delivery","volume":"122","author":"Xu","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.11.001_bib177","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202415643","article-title":"Modular design of lipopeptide-based organ-specific targeting (POST) lipid nanoparticles for highly efficient RNA delivery","volume":"37","author":"Tang","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.11.001_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1134097","article-title":"Diagnostics of atherosclerosis: overview of the existing methods","volume":"10","author":"Poznyak","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib179","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/01.ATV.9.5.567","article-title":"Immune-mechanisms in atherosclerosis","volume":"9","author":"Hansson","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.apsb.2025.11.001_bib180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(59)92108-7","article-title":"Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein","volume":"2","author":"Gero","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.11.001_bib181","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.117.031420","article-title":"Regulatory CD4+T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B","volume":"138","author":"Kimura","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2025.11.001_bib182","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.04.016","article-title":"Timing affects the efficacy of LDL immunization on atherosclerotic lesions in Apoe\u2212\/\u2212 mice","volume":"176","author":"Chyu","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2025.11.001_bib183","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.11.001_bib184","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/CIRCRESAHA.120.315942","article-title":"Vaccination strategies and immune modulation of atherosclerosis","volume":"126","author":"Nilsson","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2025.11.001_bib185","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jacc.2019.07.061","article-title":"From focal lipid storage to systemic inflammation JACC review topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:34:38Z","timestamp":1779824078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525007312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":185,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2211383525007312"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-based nanosystems for atherosclerosis treatment: Evolving approaches and novel therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}